LOW-risk evidence brief
Wellorithm vs Enhance.MD: decode $147 starting evidence, a $112 first month, and a $212 recurring statement
By Clinic Scout Editorial Team · no clinical credentials claimed · updated 2026-07-23
Direct answer
The practical difference is evidence visibility: compare the dated price, formulation, clinician-review, payment, shipping, and commitment fields before treating any headline price as a full program cost.
| Provider | Starting price | Medications offered | Insurance | Average wait | Clinic Scout score | Public review signal | Next steps |
|---|---|---|---|---|---|---|---|
| Wellorithm | Advertised from $147; later-month and dose-dependent totals require confirmation | Compounded options; the checked page says FDA has not reviewed them for safety, quality, or effectiveness | No insurance required; HSA/FSA described; reimbursement is not guaranteed | Free direct-to-door shipping stated; dispatch and delivery timing not stated | 6.2/10 | ||
| Enhance.MD | First month advertised from $112; the checked page also states $212/month | Compounded medication; not FDA-approved; online consultation required | HSA/FSA described; insurance coverage not stated | Medication shipped to the door; the checked page states a 12-week cadence but no delivery window | 5.7/10 | ||
| CareBareRX | Advertised from $199; total and ongoing cost require confirmation | Compounded semaglutide and tirzepatide referenced; compounded drugs are not FDA-approved, and the seller's brand-parenthetical wording is not repeated here | No insurance required; HSA/FSA payments described; reimbursement is not guaranteed | Free shipping stated as 1–2 days; clinician-review timing not stated | 3.9/10 | ||
| Synergy RX | GLP-1 program price not stated on the checked page | Both FDA-approved brand-name and compounded GLP-1 formulations are referenced; exact selection requires licensed-provider review | Not stated for the checked GLP-1 offer | Discreet door shipping stated; timing not stated | 2.9/10 |
The archived prices have different time labels
Wellorithm states a starting price of $147. The archived extract does not establish the later-month amount. Enhance.MD states a first month from $112 and also states $212/month. Treating all three numbers as equivalent monthly prices would erase the time period attached to each one.
For Wellorithm, ask what month two and later cost, whether the amount varies by product or dose, and what the start includes. For Enhance.MD, ask what triggers the move from $112 to $212 and whether medication, consultation, supplies, and shipping are included.
A published rate is commercial evidence, not a medical recommendation or eligibility promise.
Enhance.MD makes the first-month transition more visible
The Enhance.MD extract gives both a first-month figure and a recurring monthly figure. That reduces one common ambiguity while leaving dose changes, commitment, laboratory work, and final checkout totals to verify.
Wellorithm’s $147 language is useful as a starting point, but the archived evidence does not support the prior claim that it published a specific introductory-to-recurring step-up. The corrected comparison leaves that field unknown.
Unknown does not mean expensive or poor quality. It means the cited extract cannot support the number.
Product-status wording is explicit but distinct
Wellorithm says FDA has not reviewed the medications for safety, quality, or effectiveness. Enhance.MD states the medication is compounded and not FDA-approved.
These statements preserve the regulator distinction. A familiar ingredient, route, or pharmacy reference does not establish an FDA-approved branded product.
Ask for the exact formulation, prescriber, dispensing pharmacy, and current availability before payment.
Clinical oversight is described at different levels
Wellorithm states prescription drugs must be used under a licensed healthcare professional’s supervision. Enhance.MD states prescription products require an online consultation and describes ongoing provider care and support.
Neither statement proves that a particular person qualifies, that a prescription will be written, or that one service delivers better clinical outcomes.
Verify state licensure and follow-up channels through authoritative sources rather than relying on a marketing label alone.
Shipping evidence is incomplete for both
Wellorithm states free direct-to-door shipping but the archived extract does not state dispatch or delivery timing. Enhance.MD says medication is shipped to the door and references a 12-week cadence, not a delivery window.
A cadence describes recurrence; a delivery window describes elapsed fulfillment time. The two should not be substituted.
Ask when the pharmacy receives the prescription, which event starts the carrier clock, how tracking works, and what happens after delay or temperature excursion.
HSA/FSA language does not settle reimbursement
Wellorithm describes HSA/FSA use and no insurance requirement. Enhance.MD describes HSA/FSA use while the checked extract does not establish insurance coverage.
Merchant acceptance, account eligibility, plan reimbursement, and insurance coverage are separate commercial facts. Obtain an itemized receipt and verify plan rules.
No payment or affiliate route is active in this comparison.
Pick the question before comparing the answer
Enhance.MD provides stronger archived evidence for the transition between a first-month and recurring figure. Wellorithm provides a lower stated starting point, but later-month totals remain unresolved in the extract.
Use a worksheet that separates first charge, recurring charge, duration, medication/formulation, clinician review, pharmacy, shipping, cancellation, and unknowns.
Recheck both first-party pages immediately before any decision because price, availability, and terms can change.
Sources
- Wellorithm · supports wellorithm-vs-enhance-md-fact-1, wellorithm-vs-enhance-md-fact-2 · checked 2026-07-23
- Enhance.MD · supports wellorithm-vs-enhance-md-fact-1, wellorithm-vs-enhance-md-fact-2 · checked 2026-07-23
- HealthRX · supports wellorithm-vs-enhance-md-fact-1, wellorithm-vs-enhance-md-fact-2 · checked 2026-07-23
- Serena Health · supports wellorithm-vs-enhance-md-fact-1, wellorithm-vs-enhance-md-fact-2 · checked 2026-07-23
- FDA · supports wellorithm-vs-enhance-md-fact-1, wellorithm-vs-enhance-md-fact-2 · checked 2026-07-23
- FTC · supports wellorithm-vs-enhance-md-fact-1, wellorithm-vs-enhance-md-fact-2 · checked 2026-07-23
Next step
Use the cited sources to verify today’s terms and ask a licensed clinician about medical fit. This staged article does not choose a medication or provider for you.
Compare your priorities privately